Article
Brochure
Executive Resource
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
Weaver’s transaction advisory team highlights a recent success guiding a client through a contentious net working capital and earn-out dispute.
Weaver supported an aviation management firm with sell-side financial and tax assistance, saving the client over $1 million in post-close adjustments.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Weaver’s Transaction Advisory Services team highlights a recent success story, guiding a client through an investment in a fast-casual restaurant.
Download our white paper to learn how to even begin to measure and report GHG emissions.
False claims for fuel tax credits land on the IRS’ Dirty Dozen list of tax scams. Learn about the risks and new filing requirements.
Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.
Executive ResourceWhen a small to medium-sized business owner exits a company, the factors they need to ponder are varied and complex. Here’s an overview of those considerations.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Explore year-end considerations including the critical aspects of 45Z credits, ITC for biogas and strategies for clean fuel production credits.
Weaver has developed carbon accounting processes to determine our carbon footprint across Scope 1 and Scope 2 emissions.
